Abstract:Abstract Purpose: We plan to use a tissue microarray-based microRNA(miRNA) detection by in situ hybridization with LNA probe and support vector machine on base of data mining to construct the Prognostic model for breast cancer and triple negative breast cancer (TNBC). Methods: Combining the BreastMark miRNA database and papers published, we chose candidate miRNAs. Then a tissue microarray-based miRNA detection in situ hybridization with LNA probe was used to detect miRNA expression in 445 breast cancer tissue. Univariate analysis with Kaplan-Meier identified independent prognostic factors, 445 patients was divided into the training set and validation set (70% VS 30%) by software R(version 3.2.3), then support vector machine on base of data mining was used to construct the Prognostic model for breast cancer and triple negative breast cancer via software R and predict.svm(e1071). Results: 15 miRNAs were detected from 445 breast cancer tissue and univariate analysis with Kaplan-Meier identified significant prognostic miRNAs: miR-361-5p, miR-301a, miR-223, miR-421, miR-454, miR-493 were the independent prognostic factors for DFS. By using data mining technique, we combined clinical factors(stage, tumor size, lymphnode status, molecular subtype) and miRNAs mentioned above to establish the personalized predictive mathematical models SVM-BC and SVM-TNBC. In the training set and validation set of SVM-BC model, the AUC value of ROC curve for DFS were 0.86,0.83. The total accuracy,sensitivity,specificity of SVM-BC model for DFS were 94%,73%,99% and 84%,57%,92% in the training set and validation set. The SVM-BC model can divide breast cancer patients into high-risk and low-risk groups, and 5-year survival rates for low-risk patients were higher than that for high-risk patients(96.8% VS 39.3%, p<0.001). In the training set and validation set of SVM-TNBC model, the AUC value of ROC curve for DFS were 0.84,0.86. The total accuracy,sensitivity,specificity of SVM-TNBC model for DFS were 90%,71%,97% and 84%,55%,94% in the training set and validation set. The SVM-TNBC model can divide breast cancer patients into high-risk and low-risk groups, and 5-year survival rates for low-risk patients were higher than that for high-risk patients(93.9 % VS 23.5%, p <0.001). Conclusion: The Prognostic model basing of tissue microarray-based miRNA detection in situ hybridization with LNA probe and support vector machine for prognosis can effectively predict the prognosis of breast cancer and TNBC. Citation Format: Cao Z, Yao L, Hu X, Zhang Z, Shao Z. In-situ hybridization of microRNA and support vector machines–based prognostic classifiers for breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-37.

A Gene Signature for Breast Cancer Prognosis Using Support Vector Machine

Biomarker Discovery To Improve Prediction Of Breast Cancer Survival: Using Gene Expression Profiling, Meta-Analysis, And Tissue Validation

A 41-Gene Signature Derived from Breast Cancer Stem Cells As a Predictor of Survival

Fifteen-MiRNA-Based Signature is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients.

Multiclass Cancer Classification by Using Fuzzy Support Vector Machine and Binary Decision Tree with Gene Selection

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

A Novel Coiled-Coil Domain Containing-Related Gene Signature for Predicting Prognosis and Treatment Effect of Breast Cancer.

Four‐gene signature based on machine learning filtration could predict prognosis of patients with breast cancer

Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets

XGBoost-based and tumor-immune characterized gene signature for the prediction of metastatic status in breast cancer

A 15-gene signature for prediction of colon cancer recurrence and prognosis based on SVM

Exploring Prognostic Gene Factors in Breast Cancer via Machine Learning

Parameters Selection in Gene Selection Using Gaussian Kernel Support Vector Machines by Genetic Algorithm

Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis

Predicting gene signature in breast cancer patients with multiple machine learning models

Gene Selection for Cancer Classification using Support Vector Machines

A Signature Constructed with Mitophagy-Related Genes to Predict the Prognosis and Therapy Response for Breast Cancer.

Identification and Validation of Prognostically Relevant Gene Signature in Melanoma

Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning

Abstract P2-05-37: In-situ Hybridization of Microrna and Support Vector Machines–based Prognostic Classifiers for Breast Cancer